COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States.

Abstract

Scientific evidence is lacking regarding the risk of patients with chronic liver disease (CLD) for COVID-19, and how these risks are affected by age, gender and race. We performed a case-control study of electronic health records of 62.2 million patients (age >18 years) in the US up to October 1st, 2020, including 1,034,270 patients with CLD, 16,530 with COVID-19, and 820 with both COVID-19 and CLD. We assessed the risk, disparities, and outcomes of COVID-19 in patients with six major CLDs. Patients with a recent medical encounter for CLD were at significantly increased risk for COVID-19 compared with patients without CLD, with the strongest effect in patients with chronic non-alcoholic liver disease [adjusted odd ratio (AOR)=13.11, 95% CI: 12.49-13.76, <i>p</i> < 0.001] and non-alcoholic cirrhosis (AOR=11.53, 95% CI: 10.69-12.43, <i>p</i> < 0.001), followed by chronic hepatitis C (AOR=8.93, 95% CI:8.25-9.66, <i>p</i> < 0.001), alcoholic liver damage (AOR=7.05, 95% CI:6.30-7.88, <i>p</i> < 0.001), alcoholic liver cirrhosis (AOR=7.00, 95% CI:6.15-7.97, <i>p</i> < 0.001) and chronic hepatitis B (AOR=4.37, 95% CI:3.35-5.69, <i>p</i> < 0.001). African Americans with CLD were twice more likely to develop COVID-19 than Caucasians. Patients with COVID-19 and a recent encounter for CLD had a death rate of 10.3% (vs. 5.5% among COVID-19 patients without CLD, <i>p</i> < 0.001) and a hospitalization rate of 41.0% (vs. 23.9% among COVID-19 patients without CLD, <i>p</i> < 0.001). Patients with CLD, especially African Americans, were at increased risk for COVID-19, highlighting the need to protect these patients from exposure to virus infection. National Institutes of Health (AG057557, AG061388, AG062272, 1UL1TR002548-01), American Cancer Society (RSG-16-049-01-MPC).